Parad Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 02-11-2024
- Paid Up Capital ₹ 0.10 M
as on 02-11-2024
- Company Age 2 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.00 M
as on 02-11-2024
About Parad Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Amit Parikh, Binaben Parikh, and Sanjaya Panda serve as directors at the Company.
- CIN/LLPIN
U24231GJ2022PTC130979
- Company No.
130979
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2022
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Parad Pharmaceutical?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Parikh  | Director | 13-Apr-2022 | Current |
| Binaben Parikh | Director | 13-Apr-2022 | Current |
| Sanjaya Panda | Director | 10-Apr-2023 | Current |
Financial Performance of Parad Pharmaceutical.
Parad Pharmaceutical Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Parad Pharmaceutical?
Unlock access to Parad Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Parad Corporation Private LimitedActive 7 years 6 monthsAmit Parikh and Binaben Parikh are mutual person
_PRIVATELIMITED.webp)
Megachem Specialty Chemicals (I) Private LimitedActive 15 years 6 monthsSanjaya Panda is a mutual person
Axiom Chemicals Private LimitedActive 13 years 4 monthsAmit Parikh and Binaben Parikh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Jul 2023 | ₹5.00 M | Satisfied |
How Many Employees Work at Parad Pharmaceutical?
Parad Pharmaceutical has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parad Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parad Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
